drugset / Trial / NCT04733742

Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke

NCT04733742 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this trial is to investigate whether intravenous rhTNK-tPA prior to endovascular treatment can improve 90-day functional outcome of stroke patients with large vessel occlusion who are thrombolysis-eligible within 4.5 hours of symptom onset.

Timeline

Start
2022-05-09
Primary completion
2024-12-16
Completion
2025-02-07

Outcome

Met primary endpoint

paper Functional independence at 90 days was observed in 147 patients (52.9%) in the tenecteplase-thrombectomy group and in 120 patients (44.1%) PMID 40396577 ↗

paper unadjusted risk ratio, 1.20; 95% confidence interval, 1.01 to 1.43; P = 0.04). PMID 40396577 ↗

paper the percentage of patients with functional independence at 90 days was higher with intravenous tenecteplase plus endovascular thrombectomy than with endovascular thrombectomy alone. PMID 40396577 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenecteplase Protein / enzyme biologic — Intravenous

Indications